Humanigen Inc. (HGEN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for HGEN in the last 30 days. The most recent was published Jan 8, 2024.
Latest news
25 items- SECHumanigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HUMANIGEN, INC (0001293310) (Filer)
- NEWSHumanigen Downfall: FDA Rejection For COVID-19 Drug Triggers Financial Crisis, BankruptcyHumanigen (OTC:HGEN) has filed for bankruptcy likely as a result of the U.S. Food and Drug Administration’s (FDA) rejection of its COVID-19 drug, lenzilumab. The company, previously linked with disgraced pharmaceutical entrepreneur Martin Shkreli, reported unsecured debts of $44.1 million against assets of $521,000. The FDA’s refusal in 2021 to grant emergency-use authorization for lenzilumab significantly impacted Humanigen’s financial stability. Citing Henry Madrid, the Senior Vice President of Finance, the Wall Street Journal noted that the rejection was a key factor in the company’s financial troubles. The regulatory body concluded that the drug’s potential benefits did no
- INSIDERChappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)4 - HUMANIGEN, INC (0001293310) (Issuer)
- SECSEC Form 25-NSE filed by Humanigen Inc.25-NSE - HUMANIGEN, INC (0001293310) (Subject)
- SECHumanigen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - HUMANIGEN, INC (0001293310) (Filer)
- SECSEC Form NT 10-Q filed by Humanigen Inc.NT 10-Q - HUMANIGEN, INC (0001293310) (Filer)
- NEWSCrude Oil Up 1%; Verizon Earnings Beat ViewsU.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05. The S&P 500, also rose, gaining, 0.48% to 4,576.60. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying Leading and Lagging Sectors Materials shares climbed by 1.8% on Tuesday. In trading on Tuesday, real estate shares fell by 0.6%. Top Headline Verizon Communications Inc (NYSE:VZ) reported better-than-expected earnings for its second quarter. It clocked a sales decline of 3.5% year-on-year to $32.6 billion, missing the consensus of $33.3 billion. Ad
- NEWS12 Health Care Stocks Moving In Tuesday's Intraday SessionGainers Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 33.8% to $4.63 during Tuesday's regular session. Trading volume for Bullfrog AI Hldgs's stock is 42.6 million as of 13:30 EST. This is 8458.3% of its average full-day volume over the last 100 days. The company's market cap stands at $28.2 million. Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock rose 32.66% to $19.82. Trading volume for Kiniksa Pharmaceuticals's stock is 3.0 million as of 13:30 EST. This is 719.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 billion. As per the press release, Q2 earnings came out today. Galecto (NASDAQ:GLTO) shares rose 28.51% to $3.02. As of 13:30
- NEWSWhy Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionGainers Aurora Acquisition Corp. (NASDAQ:AURC) shares jumped 192% to $30.54. Inpixon (NASDAQ:INPX) gained 117% to $0.33 after the company agreed to merge with XTI Aircraft Company. Electra Battery Materials Corporation (NASDAQ:ELBM) shares shot up 71.5% to $2.11 after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022. Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares gained 35.3% to $4.68 after the company announced US patent for novel prodrugs of mebendazole and their use in treating cancer. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) climb
- NEWSStocks That Hit 52-Week Lows On TuesdayOn Tuesday, 56 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS). 9 Meters Biopharma (NASDAQ:NMTR) was the smallest company by market cap to set a new 52-week low. Humanigen (NASDAQ:HGEN)'s stock came under the most pressure, trading down 73.22% to reach a new 52-week low. NeuBase Therapeutics (NASDAQ:NBSE) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. On Tuesday, the following stocks set new 52-week lows: Apellis Pharmaceuticals (NASDAQ:APLS) stock drifted down 2.25% on Tuesday morning to hi
- NEWSDow Surges 50 Points; General Electric Profit Tops ExpectationsU.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 50 points on Tuesday. The Dow traded up 0.16% to 35,468.65 while the NASDAQ rose 0.60% to 14,142.63. The S&P 500, also rose, gaining, 0.27% to 4,566.98. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying Leading and Lagging Sectors Materials shares climbed by 1.8% on Tuesday. In trading on Tuesday, financial shares fell by 0.4%. Top Headline General Electric Co (NYSE:GE) reported better-than-expected results for its second quarter. General Electric reported second-quarter FY23 revenues of $16.70 billion, an increase of 18% year-over-year, beating the consensus
- NEWSNasdaq Rises 70 Points; General Motors Posts Upbeat EarningsU.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 70 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 35,393.00 while the NASDAQ rose 0.50% to 14,129.68. The S&P 500, also rose, gaining, 0.13% to 4,560.43. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying Top Headline General Motors Company (NYSE:GM) reported better-than-expected earnings for its second quarter. General Motors posted quarterly earnings of $1.91 per share, beating market estimates of $1.85 per share. The company’s quarterly sales came in at $44.75 billion versus expectations of $42.64 billion. GM said it sees FY23 adju
- NEWS12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 45.4% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $30.6 million. Enzo Biochem (NYSE:ENZ) shares rose 16.91% to $1.59. The market value of their outstanding shares is at $79.0 million. Aravive (NASDAQ:ARAV) shares moved upwards by 14.09% to $1.7. The market value of their outstanding shares is at $101.7 million. Novan (NASDAQ:NOVN) stock increased by 11.5% to $0.14. The market value of their outstanding shares is at $3.9 million. Biotricity (NASDAQ:BTCY) stock rose 10.72% to $3.51. The market value of their outstanding shares is at $30.7 million. Alpha Tau Medical (NASDAQ:DRTS) stock move
- NEWSHumanigen Said It Anticipates That It Will Not Be Able To Continue As A Going Concern And Is Exploring All Restructuring Options, Including Bankruptcy-8-K
- SECHumanigen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits8-K - HUMANIGEN, INC (0001293310) (Filer)
- NEWS12 Health Care Stocks Moving In Monday's After-Market SessionGainers Biofrontera (NASDAQ:BFRI) shares rose 52.2% to $0.67 during Monday's after-market session. At the close, Biofrontera's trading volume reached 2.3 million shares. This is 3249.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $17.8 million. Tivic Health Systems (NASDAQ:TIVC) stock rose 31.87% to $0.13. Today's trading volume for this security ended up closing at 5.9 million shares, which is 210.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $3.8 million. Cano Health (NYSE:CANO) stock increased by 25.6% to $1.57. Trading volume for this security closed at 2.1 million, accoun
- NEWSWhy Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day SessionGainers Oncorus, Inc. (NASDAQ:ONCR) shares surged 258% to $0.2781. Evelo Biosciences, Inc. (NASDAQ:EVLO) shares jumped 216.2% to $0.2622 after the company won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome. Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) gained 58% to $0.1296. Navidea Biopharmaceutical recently posted a narrower first-quarter loss. Virgin Galactic Holdings, Inc. (NYSE:SPCE) shares climbed 32.1% to $5.36 as the company announced the start of commercial spaceline operations. The company said its first commercial spaceflight, "Galactic 01," is set to fly between June 27 and June 30. Plutonian Acquisition Corp. (NASDAQ:PL
- NEWS12 Health Care Stocks Moving In Friday's Pre-Market SessionGainers Evelo Biosciences (NASDAQ:EVLO) shares rose 320.3% to $0.35 during Friday's pre-market session. The company's market cap stands at $39.0 million. Surface Oncology (NASDAQ:SURF) shares moved upwards by 32.22% to $0.98. The company's market cap stands at $59.4 million. Humanigen (NASDAQ:HGEN) stock increased by 26.25% to $0.2. The company's market cap stands at $24.0 million. Oncorus (NASDAQ:ONCR) shares increased by 23.32% to $0.1. The company's market cap stands at $2.4 million. Know Labs (AMEX:KNW) shares moved upwards by 16.19% to $1.22. The company's market cap stands at $59.1 million. Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 15.14% to $1.07. The market value
- NEWSWhy Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving PremarketGainers Evelo Biosciences, Inc. (NASDAQ:EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use Thereof For Modulation Of The Microbiome." Plutonian Acquisition Corp. (NASDAQ:PLTNR) shares surged 42.4% to $0.47 in pre-market trading after jumping 32% on Thursday. Humanigen, Inc. (NASDAQ:HGEN) shares rose 39.2% to $0.2227 in pre-market trading. Humanigen recently presented promising new hematologic data from PREACH-M trial for chronic myelomonocytic leukemia treatment at the 2023 European Hematology Association Congress. Virgin Galactic Holdings, Inc. (NYSE:SPCE) shares rose 38.7% to
- NEWSHumanigen Granted U.S. Patent Titled 'METHOD OF INCREASING THE EFFICACY OF CAR-T IMMUNOTHERAPY USING LENZILUMAB'chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11673962
- SECSEC Form 10-Q filed by Humanigen Inc.10-Q - HUMANIGEN, INC (0001293310) (Filer)
- SECSEC Form 10-K/A filed by Humanigen Inc. (Amendment)10-K/A - HUMANIGEN, INC (0001293310) (Filer)
- NEWSOn April 18, 2023, Humanigen Was Notified That It Had Been Granted An Extension Until August 21, 2023 By Nasdaq To Demonstrate Compliance With All Applicable Requirements For Listing Of The Company's Common Stock8-K
- SECHumanigen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HUMANIGEN, INC (0001293310) (Filer)
- NEWSHumanigen Tweets 'Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (CMML), An Orphan Form Of Leukemia'https://www.newsfilecorp.com/release/162136
HGEN FAQ
7 questionsWhat does Humanigen Inc. do?
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory...What is the latest news on HGEN?
Quantisnow has not tracked any new filings, ratings or press releases for HGEN in the last 30 days. The most recent wire item was published on January 8, 2024.Where does HGEN stock trade?
Humanigen Inc. (HGEN) is listed on NASDAQ.What sector and industry is HGEN in?
Humanigen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HGEN?
Across the last 8 analyst actions on Humanigen Inc., there were 0 upgrades and 6 downgrades. The most recent action was from ROTH Capital: Neutral with a $2.00 price target on 2022-07-13.What companies are similar to HGEN?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare HGEN side-by-side with any of them on Quantisnow.How can I track HGEN on Quantisnow?
Quantisnow aggregates Humanigen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HGEN to receive live email and push alerts on every new disclosure.